Provided by Tiger Trade Technology Pte. Ltd.

Alpha Tau Medical

9.35
-0.9400-9.14%
Post-market: 9.670.3238+3.46%19:58 EDT
Volume:1.39M
Turnover:13.25M
Market Cap:822.89M
PE:-14.16
High:10.29
Open:10.27
Low:9.13
Close:10.29
52wk High:11.62
52wk Low:2.82
Shares:88.01M
Float Shares:57.35M
Volume Ratio:0.75
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6603
EPS(LYR):-0.5300
ROE:-90.51%
ROA:-30.50%
PB:11.87
PE(LYR):-17.64

Loading ...

Top Executive Makes Major Move With Alpha Tau Medical Stock

TIPRANKS
·
Jun 05

Alpha Tau Medical CFO Raphi Levy disposes of $352,606 in common shares

Reuters
·
Jun 05

Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 04

Alpha Tau Medical Is Maintained at Overweight by Barclays

Dow Jones
·
Jun 04

Alpha Tau Medical Ltd (DRTS) Receives a Buy from Barclays

TIPRANKS
·
Jun 04

Alpha Tau, Tolmar announce strategic collaboration agreement

TIPRANKS
·
Jun 03

Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy

MT Newswires Live
·
Jun 03

Alpha Tau, Tolmar partner to develop, commercialize Alpha DaRT for U.S. prostate cancer patients

Reuters
·
Jun 03

Alpha Tau Medical - Tolmar Granted Exclusive U.S. Rights for Prostate Cancer, Option for Bladder Cancer

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical - Tolmar to Invest $15M in Manufacturing, $20M Equity at $11.99/Share, up to $161.5M in Milestones

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical - to Manufacture Alpha Dart for Tolmar at 60% of Net Sales Price

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical - up to $96.5M in Development and $65M in Commercial Milestone Payments Agreed

THOMSON REUTERS
·
Jun 03

Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 03

Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer

MT Newswires Live
·
Jun 01

Alpha Tau reports 11.2-month median survival in pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026

Reuters
·
Jun 01

Alpha Tau Announces Strong Overall Survival Results From Alpha Dart® Pancreatic Cancer Studies Presented at 2026 Asco Annual Meeting

THOMSON REUTERS
·
Jun 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Alpha Tau Medical Initiated at Overweight by Barclays

Dow Jones
·
May 28

Barclays Initiates Alpha Tau Medical With Overweight Rating, $15 Price Target

MT Newswires Live
·
May 28

Alpha Tau :  Barclays Initiates Coverage With Overweight Rating and Target Price $15

THOMSON REUTERS
·
May 28